报价延迟最少15分钟:2026/03/02 10:07 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.1504 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.54/-0.78
|
|
企业价值
273.29M
|
| 资产负债 |
|
每股账面净值
0.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company. |
